Poor
Not Aligned
Patient Risk:
Moderate
Summary
Overall alignment is poor because multiple material claims about indication-specific dosing (AF and DVT/PE maintenance) and food administration are not supported by the provided label excerpts, and several safety/clinical-counseling statements are overgeneralized or not explicitly listed in the supplied sections.
Category Scores
Accurate Statements
Patients should not double up if they miss a dose.
2.3 Missed Dose: "The dose should not be doubled to make up for a missed dose."
After missing a dose, patients should resume twice-daily administration and continue the same-day schedule.
2.3 Missed Dose: "taken as soon as possible on the same day and twice-daily administration should be resumed."
Combining Eliquis with other anticoagulants or antiplatelet drugs can increase bleeding risk.
5.2 Bleeding and 7.3: "Concomitant use of drugs affecting hemostasis... includes aspirin and other antiplatelet agents, other anticoagulants... increases the risk of bleeding."
Unsupported Statements
For atrial fibrillation (AF), Eliquis is usually taken as 5 mg twice daily (about every 12 hours).
No AF indication or dosing specifics are present in the provided label excerpts.
For AF, some patients need a lower dose based on clinical criteria such as age, serum creatinine, and body weight.
No AF dose-reduction criteria are included in the provided excerpts.
Dose reduction from 5 mg to 2.5 mg (still twice daily) can apply for certain AF patients based on prespecified characteristics such as older age, impaired kidney function, low body weight, or other qualifying factors.
No AF-specific dose-reduction framework is included in the provided excerpts.
Dose reduction criteria are meant to lower bleeding risk.
The provided excerpts discuss bleeding risk and interaction-based dose reduction/avoidance, but do not state that AF-specific dose reduction criteria are intended to lower bleeding risk.
After treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE)... includes a maintenance regimen that includes 5 mg twice daily in many patients.
No DVT/PE indications or maintenance dosing are present in the provided excerpts.
Eliquis can usually be taken with or without food.
No food-with/without guidance appears in the provided label excerpts.
The main risk on Eliquis is bleeding.
While bleeding is described as an increased risk, the provided excerpts do not state that bleeding is the "main" risk.
Signs of bleeding that may occur include unusual bruising, nose/gum bleeding, blood in urine or stool, vomiting blood, or coughing blood.
The provided excerpts instruct to advise patients of signs/symptoms of blood loss and to report them, but do not list the specific examples enumerated in the claim.
Patients are often screened for strong inhibitors/inducers of CYP3A4 and P-glycoprotein.
No screening/testing language is included in the provided excerpts.
Combination therapy with other anticoagulants or antiplatelet drugs may be appropriate under clinician direction and requires careful selection and monitoring.
The excerpts support increased bleeding risk with concomitant hemostasis-affecting drugs, but do not provide labeling support for this "may be appropriate"/"careful selection and monitoring" nuance.
Contradictions
Important Omissions
AF indication and dosing guidance (including dose-reduction criteria) cannot be verified from the provided label excerpts, which is material to the dosing-related claims made.
Importance:
High
DVT/PE indication-specific dosing/maintenance regimen cannot be verified from the provided label excerpts, which is material to the DVT/PE dosing claim made.
Importance:
High
Food administration guidance (with/without food) is not present in the provided excerpts; this is material because the claim asserts general administration guidance.
Importance:
Moderate
Specific bleeding-sign examples asserted in the counseling claim are not present in the provided excerpts, making the counseling content potentially incomplete/misaligned.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Material dosing claims for AF and DVT/PE regimens are not supported by the provided label excerpts, creating potential dosing safety risk. Some safety-counseling statements (relative-risk framing and specific bleeding sign examples) are not explicitly supported by the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Indication-specific dosing (AF; DVT/PE maintenance) and food-administration guidance are unsupported by the provided label excerpts; multiple safety counseling details are also not explicitly supported.
Suggested Improvement
Restrict statements to what is supported by the provided label excerpts (e.g., missed-dose instruction; bleeding risk with concomitant hemostasis-affecting drugs; interaction management with combined P-gp and strong CYP3A4 inhibitors/inducers) and omit or re-cite label sections for AF dosing, dose-reduction criteria, DVT/PE maintenance dosing, and food-with/without guidance.